SCHEMBL6773443

SCHEMBL6773443

CCOC(=O)CC(NC(=O)CNC(=O)c1cccc([N+](=O)[O-])c1)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 6/20 0.48
LMNA P02545 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ATM Q13315 1/20 0.48
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
MAPT P10636 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
CACNA1B Q00975 1/20 0.45
APBA1 Q02410 1/20 0.45
ROCK2 O75116 1/20 0.44
GAA P10253 1/20 0.44
G6PD P11413 1/20 0.44
IRAK1 P51617 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3834631 0.89 ALDH1A1 (0.54) KMT2AALDH1A1LMNAKDM4EATM
SCHEMBL6779290 0.86 ROCK2 (0.46) KMT2AALDH1A1ATMMEN1MAPT
SCHEMBL5352252 0.85 ALDH1A1 (0.51) KMT2AALDH1A1LMNAKDM4EATM
SCHEMBL7339949 0.83 ROCK2 (0.44) ALDH1A1MAPTHPGDSMN1; SMN2POLB
SCHEMBL6772228 0.82 GPR139 (0.43) KMT2AALDH1A1MEN1HTTMAPT
SCHEMBL7835665 0.82 ITGB3 (0.45) ALDH1A1MAPTHPGDSMN1; SMN2POLB
SCHEMBL6773670 0.82 ROCK2 (0.43) KMT2AALDH1A1KDM4EMEN1MAPT
SCHEMBL6773448 0.81 KMT2A (0.55) KMT2AALDH1A1LMNAKDM4EATM
SCHEMBL7832728 0.81 ROCK2 (0.42) KMT2AALDH1A1ATMMEN1MAPT
Trifluoroacetic Acid SCHEMBL6773199 0.81 ROCK2 (0.42) KMT2AATMMEN1SMN1; SMN2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed